MOTS-c K14Q: What Genetic Association Studies of an East Asian Mitochondrial Variant Show for Type 2 Diabetes, Muscle Fibre and Sarcopenia Research

RESEARCH · MOTS-c · K14Q GENETIC VARIANT

MOTS-c K14Q: What Genetic Association Studies of an East Asian Mitochondrial Variant Show for Type 2 Diabetes, Muscle Fibre and Sarcopenia Research

PurixLab’s MOTS-C 10mg is a research vial of a 16-amino-acid peptide encoded in mitochondrial DNA. Our earlier articles cover exercise and AMPK signalling, circulating levels in human observational studies and the wider mitochondrial-derived peptide family. This article looks at a different kind of evidence: a naturally occurring variant in the MOTS-c sequence and what population-genetics studies have reported about its carriers. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

What the K14Q variant is

MOTS-c was first described as a peptide encoded within the mitochondrial 12S rRNA gene, whose cellular actions inhibit the folate cycle and activate AMPK, with skeletal muscle as its apparent primary target organ [1]. In 2015, Fuku and colleagues pointed out that the m.1382A>C polymorphism lies in the MOTS-c encoding sequence and is specific for the Northeast Asian population. Their paper was a hypothesis, suggesting that the variant may be among the putative biological mechanisms behind the high longevity of Japanese people, and it stated that more research was needed [2]. The A-to-C change replaces the 14th amino acid, lysine (K), with glutamine (Q), hence “K14Q” [3]. Because it sits in the mitochondrial genome, it is inherited maternally, and a PubMed search for the variant’s identifier (rs111033358) run on 2026-11-03 returned only two records, so the dedicated human evidence base is small.

Type 2 diabetes cohorts and the mouse test

Zempo and colleagues combined three Japanese cohorts (J-MICC, MEC and TMM; n = 27,527) in a meta-analysis. Males, but not females, with the C allele had a higher prevalence of type 2 diabetes. In J-MICC the increase appeared only in males in the lowest tertile of physical activity, which the authors described as a kinesio-genomic interaction [3]. The same paper tested the sequence change directly. In high-fat-fed male mice, wild-type MOTS-c reduced weight and improved glucose tolerance, but K14Q-MOTS-c did not; female mice were unaffected, and K14Q-MOTS-c produced diminished insulin sensitisation in cell culture [3].

Muscle fibre type and athletes

Kumagai and colleagues studied the variant against a muscle phenotype. Among 211 healthy Japanese individuals, C-allele carriers had a higher proportion of MHC-IIx, a marker of fast-twitch fibre. In 86 physically active young men, C-allele carriers had higher peak torques of leg flexion and extension. The C allele frequency ordered as 6.5% in sprint/power athletes, 5.1% in controls and 2.9% in endurance athletes, drawn from 721 athletes and 873 controls. To mimic the C allele, young male mice received a MOTS-c neutralising antibody weekly for four weeks and showed higher expression of fast myosin than controls [4]. An earlier study of healthy men also reported an association between MOTS-c and markers of slow-type muscle [5], and with the observation that exercise induces endogenous MOTS-c expression in muscle and in circulation [6]. A review of mtDNA variants in sports genetics places K14Q alongside better-established markers such as ACTN3 and ACE [7].

Older adults and sarcopenia: two cohorts, different framing

  • Korean cohort. In 683 community-dwelling adults aged 65 and over (345 men, 338 women), men carrying the C allele had higher appendicular skeletal muscle mass (21.6 vs 19.5 kg, p = 0.018), lean mass and handgrip strength than men carrying the A allele, and the differences remained after adjustment for covariates. No genotype differences were found in women. The author proposed the variant as a possible genetic biomarker of sarcopenia in older Korean men [8]. The abstract does not report how many men carried the C allele.
  • Japanese and mechanistic data. In a later paper that also tested the variant peptide, male K14Q carriers exhibited a higher risk of sarcopenia and type 2 diabetes in an age- and physical-activity-dependent manner, while females had an age-specific reduced risk of type 2 diabetes [9].

These two reports do not point in the same direction for muscle in older men. Cohort ethnicity, age range, outcome definition and activity levels differ, and the second paper explicitly describes an age- and activity-dependent pattern. Neither dataset alone resolves the question.

A molecular clue: reduced CK2 binding

The CK2 study also supplies a mechanistic reading. MOTS-c directly bound CK2 and activated it in cell-free systems, and in mice MOTS-c administration prevented skeletal muscle atrophy and enhanced muscle glucose uptake, effects that were blunted when CK2 activity was suppressed. K14Q MOTS-c showed reduced binding to CK2 and did not activate it or elicit its effects [9]. This is consistent with the earlier cell-culture and mouse finding that the variant peptide is less active [3,4], and it gives a testable explanation for why sequence identity matters in experiments.

A study with no carriers

Not every variant study finds carriers. Filibeli and colleagues compared 121 adolescents with polycystic ovary syndrome with 125 controls, measuring serum MOTS-c by ELISA and sequencing m.1382A>C. Serum levels were higher in the PCOS group but the difference did not reach statistical significance (p = 0.059), and all participants had the wild-type A/A genotype, so no variant association could be tested [10]. The abstract does not state the participants’ ancestry; the absence of carriers is compatible with reports that the variant is East Asian-specific [4,8].

What remains open

  • Population specificity. The variant is reported as East Asian-specific, so findings cannot be assumed to apply to other ancestries [2,4,8].
  • Sex differences. Several reports see effects in males only, or a different pattern in females, and the reason has not been established [3,8,9].
  • Gene-environment interaction. Physical activity changed the diabetes association, so cohort activity data matter for interpretation [3,9].
  • Conflicting muscle signals. Higher muscle mass in older Korean carrier men sits uneasily beside a reported higher sarcopenia risk in another analysis [8,9].
  • Sequence matters in the lab. Because K14Q peptide shows reduced activity, experiments need to state the exact sequence studied [3,9].

MOTS-C 10mg at PurixLab

MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Product page: purixlab.com/product/mots-c-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View MOTS-C 10mg

Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
  2. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015;14(6):921-3. PubMed 26289118 · PMC4693465 · doi:10.1111/acel.12389
  3. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PubMed 33468709 · PMC7880332 · doi:10.18632/aging.202529
  4. Kumagai H, Natsume T, Kim SJ, et al. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochim Biophys Acta Gen Subj. 2022;1866(2):130048. PubMed 34728329 · PMC8741734 · doi:10.1016/j.bbagen.2021.130048
  5. D'Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020;12(6):5244-5258. PubMed 32182209 · PMC7138593 · doi:10.18632/aging.102944
  6. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed 33473109 · PMC7817689 · doi:10.1038/s41467-020-20790-0
  7. Kumagai H, Miller B, Kim SJ, et al. Novel Insights into Mitochondrial DNA: Mitochondrial Microproteins and mtDNA Variants Modulate Athletic Performance and Age-Related Diseases. Genes (Basel). 2023;14(2):286. PubMed 36833212 · PMC9956216 · doi:10.3390/genes14020286
  8. Kim S. The Relationship Between MOTS-c K14Q Polymorphism and Sarcopenia, Blood Lipids, and Mental Health in Older Korean Adults. Biomedicines. 2024;12(10):2384. PubMed 39457696 · PMC11504729 · doi:10.3390/biomedicines12102384
  9. Kumagai H, Kim SJ, Miller B, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024;27(11):111212. PubMed 39559755 · PMC11570452 · doi:10.1016/j.isci.2024.111212
  10. Filibeli BE, Dedemoglu F, Garipçin P, et al. Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome? Arch Endocrinol Metab. 2026;70(3):e260031. PubMed 41945630 · PMC13055642 · doi:10.20945/2359-4292-2026-0031

Leave a Comment

Your email address will not be published. Required fields are marked *